Market Overview

UPDATE: JMP Securities Reiterates on Depomed Following Acquisition of Migraine Asset

Share:
Related DEPO
Proxy Battle: What's Happening Between Starboard And DepoMed?
Activist Investor Reaffirms Stance On Depomed, Says 'Meaningful Change Is Needed'

In a report published Wednesday, JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating on Depomed (NASDAQ: DEPO), and raised the price target from $10.00 to $11.00.

In the report, JMP Securities noted, “Acquisition of migraine asset makes strategic and financial sense; reiterate Market Outperform rating and increasing price target from $10 to $11 on Depomed, Inc. Yesterday, Depomed announced the acquisition of CAMBIA, a formulation of the NSAID diclofenac approved for the treatment of migraine. Depomed will pay Nautilus Neurosciences $48.7MM upfront to acquire the product, representing ~2.7x the current annualized sales run rate, and stated that the transaction is expected to be immediately accretive. We view the product as a good strategic fit for Depomed, leveraging the company's established neurology-focused sales organization. We have updated our model to include sales of CAMBIA, which increases our 2014 and 2015 revenue estimates by 23% and 21%, respectively. We are increasing our price target from $10 to $11, now including CAMBIA in our sum-of-the-parts NPV analysis.”

Depomed closed on Tuesday at $8.34.

Latest Ratings for DEPO

DateFirmActionFromTo
Mar 2016Northland SecuritiesInitiates Coverage onOutperform
Mar 2016Leerink SwannInitiates Coverage onOutperform
Feb 2016UBSInitiates Coverage onBuy

View More Analyst Ratings for DEPO
View the Latest Analyst Ratings

Posted-In: Jason N. Butler JMP SecuritiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (DEPO)

View Comments and Join the Discussion!